1
|
Largeot A, Klapp V, Viry E, Gonder S, Fernandez Botana I, Blomme A, Benzarti M, Pierson S, Duculty C, Marttila P, Wierz M, Gargiulo E, Pagano G, An N, El Hachem N, Perez Hernandez D, Chakraborty S, Ysebaert L, François JH, Cortez Clemente S, Berchem G, Efremov DG, Dittmar G, Szpakowska M, Chevigné A, Nazarov PV, Helleday T, Close P, Meiser J, Stamatopoulos B, Désaubry L, Paggetti J, Moussay E. Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL. Blood 2023; 141:3166-3183. [PMID: 37084385 PMCID: PMC10646824 DOI: 10.1182/blood.2022017839] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Revised: 02/08/2023] [Accepted: 03/05/2023] [Indexed: 04/23/2023] Open
Abstract
Dysregulation of messenger RNA (mRNA) translation, including preferential translation of mRNA with complex 5' untranslated regions such as the MYC oncogene, is recognized as an important mechanism in cancer. Here, we show that both human and murine chronic lymphocytic leukemia (CLL) cells display a high translation rate, which is inhibited by the synthetic flavagline FL3, a prohibitin (PHB)-binding drug. A multiomics analysis performed in samples from patients with CLL and cell lines treated with FL3 revealed the decreased translation of the MYC oncogene and of proteins involved in cell cycle and metabolism. Furthermore, inhibiting translation induced a proliferation arrest and a rewiring of MYC-driven metabolism. Interestingly, contrary to other models, the RAS-RAF-(PHBs)-MAPK pathway is neither impaired by FL3 nor implicated in translation regulation in CLL cells. Here, we rather show that PHBs are directly associated with the eukaryotic initiation factor (eIF)4F translation complex and are targeted by FL3. Knockdown of PHBs resembled FL3 treatment. Importantly, inhibition of translation controlled CLL development in vivo, either alone or combined with immunotherapy. Finally, high expression of translation initiation-related genes and PHBs genes correlated with poor survival and unfavorable clinical parameters in patients with CLL. Overall, we demonstrated that translation inhibition is a valuable strategy to control CLL development by blocking the translation of several oncogenic pathways including MYC. We also unraveled a new and direct role of PHBs in translation initiation, thus creating new therapeutic opportunities for patients with CLL.
Collapse
MESH Headings
- Humans
- Mice
- Animals
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Eukaryotic Initiation Factor-4F/genetics
- Prohibitins
- Genes, myc
- RNA, Messenger/genetics
Collapse
Affiliation(s)
- Anne Largeot
- Department of Cancer Research, Tumor Stroma Interactions, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Vanessa Klapp
- Department of Cancer Research, Tumor Stroma Interactions, Luxembourg Institute of Health, Luxembourg, Luxembourg
- Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Elodie Viry
- Department of Cancer Research, Tumor Stroma Interactions, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Susanne Gonder
- Department of Cancer Research, Tumor Stroma Interactions, Luxembourg Institute of Health, Luxembourg, Luxembourg
- Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Iria Fernandez Botana
- Department of Cancer Research, Tumor Stroma Interactions, Luxembourg Institute of Health, Luxembourg, Luxembourg
- Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Arnaud Blomme
- Laboratory of Cancer Signaling, GIGA Stem Cells, University of Liège, Liège, Belgium
| | - Mohaned Benzarti
- Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
- Department of Cancer Research, Cancer Metabolism Group, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Sandrine Pierson
- Department of Cancer Research, Tumor Stroma Interactions, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Chloé Duculty
- Department of Cancer Research, Tumor Stroma Interactions, Luxembourg Institute of Health, Luxembourg, Luxembourg
- Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Petra Marttila
- Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institutet, Solna, Sweden
| | - Marina Wierz
- Department of Cancer Research, Tumor Stroma Interactions, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Ernesto Gargiulo
- Department of Cancer Research, Tumor Stroma Interactions, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Giulia Pagano
- Department of Cancer Research, Tumor Stroma Interactions, Luxembourg Institute of Health, Luxembourg, Luxembourg
- Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Ning An
- Laboratory of Cancer Signaling, GIGA Stem Cells, University of Liège, Liège, Belgium
| | - Najla El Hachem
- Laboratory of Cancer Signaling, GIGA Stem Cells, University of Liège, Liège, Belgium
| | - Daniel Perez Hernandez
- Department of Infection and Immunity, Proteomics of Cellular Signaling, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg
| | - Supriya Chakraborty
- Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | - Loïc Ysebaert
- Haematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
| | - Jean-Hugues François
- Laboratoire d’hématologie, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
| | - Susan Cortez Clemente
- Département d’hémato-oncologie, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
| | - Guy Berchem
- Département d’hémato-oncologie, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
- Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Dimitar G. Efremov
- Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | - Gunnar Dittmar
- Department of Infection and Immunity, Proteomics of Cellular Signaling, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg
- Department of Life Sciences and Medicine, University of Luxembourg, Belvaux, Luxembourg
| | - Martyna Szpakowska
- Department of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg
| | - Andy Chevigné
- Department of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg
| | - Petr V. Nazarov
- Department of Cancer Research, Multiomics Data Science, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Thomas Helleday
- Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institutet, Solna, Sweden
- Department of Oncology and Metabolism, Weston Park Cancer Centre, The Medical School, University of Sheffield, Sheffield, United Kingdom
| | - Pierre Close
- Laboratory of Cancer Signaling, GIGA Stem Cells, University of Liège, Liège, Belgium
- WELBIO Department, WEL Research Institute, Wavre, Belgium
| | - Johannes Meiser
- Department of Cancer Research, Cancer Metabolism Group, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Basile Stamatopoulos
- Laboratory of Clinical Cell Therapy, ULB-Research Cancer Center, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium
| | - Laurent Désaubry
- Regenerative Nanomedicine Laboratory (UMR1260), Faculty of Medicine, Fédération de Médecine Translationnelle de Strasbourg, INSERM-University of Strasbourg, Strasbourg, France
| | - Jérôme Paggetti
- Department of Cancer Research, Tumor Stroma Interactions, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Etienne Moussay
- Department of Cancer Research, Tumor Stroma Interactions, Luxembourg Institute of Health, Luxembourg, Luxembourg
| |
Collapse
|
2
|
Green AC, Marttila P, Kiweler N, Chalkiadaki C, Wiita E, Cookson V, Lesur A, Eiden K, Bernardin F, Vallin KSA, Borhade S, Long M, Ghahe EK, Jiménez-Alonso JJ, Jemth AS, Loseva O, Mortusewicz O, Meyers M, Viry E, Johansson AI, Hodek O, Homan E, Bonagas N, Ramos L, Sandberg L, Frödin M, Moussay E, Slipicevic A, Letellier E, Paggetti J, Sørensen CS, Helleday T, Henriksson M, Meiser J. Formate overflow drives toxic folate trapping in MTHFD1 inhibited cancer cells. Nat Metab 2023; 5:642-659. [PMID: 37012496 PMCID: PMC10132981 DOI: 10.1038/s42255-023-00771-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Accepted: 02/28/2023] [Indexed: 04/05/2023]
Abstract
Cancer cells fuel their increased need for nucleotide supply by upregulating one-carbon (1C) metabolism, including the enzymes methylenetetrahydrofolate dehydrogenase-cyclohydrolase 1 and 2 (MTHFD1 and MTHFD2). TH9619 is a potent inhibitor of dehydrogenase and cyclohydrolase activities in both MTHFD1 and MTHFD2, and selectively kills cancer cells. Here, we reveal that, in cells, TH9619 targets nuclear MTHFD2 but does not inhibit mitochondrial MTHFD2. Hence, overflow of formate from mitochondria continues in the presence of TH9619. TH9619 inhibits the activity of MTHFD1 occurring downstream of mitochondrial formate release, leading to the accumulation of 10-formyl-tetrahydrofolate, which we term a 'folate trap'. This results in thymidylate depletion and death of MTHFD2-expressing cancer cells. This previously uncharacterized folate trapping mechanism is exacerbated by physiological hypoxanthine levels that block the de novo purine synthesis pathway, and additionally prevent 10-formyl-tetrahydrofolate consumption for purine synthesis. The folate trapping mechanism described here for TH9619 differs from other MTHFD1/2 inhibitors and antifolates. Thus, our findings uncover an approach to attack cancer and reveal a regulatory mechanism in 1C metabolism.
Collapse
Affiliation(s)
- Alanna C Green
- Weston Park Cancer Centre and Mellanby Centre for Musculoskeletal Research, Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK
| | - Petra Marttila
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
| | - Nicole Kiweler
- Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Christina Chalkiadaki
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
| | - Elisée Wiita
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
| | - Victoria Cookson
- Weston Park Cancer Centre and Mellanby Centre for Musculoskeletal Research, Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK
| | - Antoine Lesur
- Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Kim Eiden
- Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - François Bernardin
- Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Karl S A Vallin
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
- RISE Research Institutes of Sweden, Södertälje, Sweden
| | - Sanjay Borhade
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
- RedGlead Discover, Lund, Sweden
| | - Maeve Long
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
| | - Elahe Kamali Ghahe
- Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark
| | - Julio J Jiménez-Alonso
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
- Department of Pharmacology, Faculty of Pharmacy, University of Seville, Seville, Spain
| | - Ann-Sofie Jemth
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
| | - Olga Loseva
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
| | - Oliver Mortusewicz
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
| | - Marianne Meyers
- Faculty of Science, Technology and Medicine, Department of Life Sciences and Medicine, Molecular Disease Mechanisms Group, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Elodie Viry
- Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Annika I Johansson
- Swedish Metabolomics Centre, Department of Plant Physiology, Umeå University, Umeå, Sweden
| | - Ondřej Hodek
- Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, Umeå, Sweden
| | - Evert Homan
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
| | - Nadilly Bonagas
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
| | - Louise Ramos
- Weston Park Cancer Centre and Mellanby Centre for Musculoskeletal Research, Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK
| | - Lars Sandberg
- Drug Discovery and Development Platform, Science for Life Laboratory, Department of Organic Chemistry, Stockholm University, Solna, Sweden
| | - Morten Frödin
- Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark
| | - Etienne Moussay
- Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Ana Slipicevic
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
- One-carbon Therapeutics AB, Stockholm, Sweden
| | - Elisabeth Letellier
- Faculty of Science, Technology and Medicine, Department of Life Sciences and Medicine, Molecular Disease Mechanisms Group, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Jérôme Paggetti
- Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | | | - Thomas Helleday
- Weston Park Cancer Centre and Mellanby Centre for Musculoskeletal Research, Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK.
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
| | - Martin Henriksson
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
| | - Johannes Meiser
- Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
| |
Collapse
|
3
|
Gargiulo E, Giordano M, Niemann CU, Moussay E, Paggetti J, Morande PE. The protective role of the microenvironment in hairy cell leukemia treatment: Facts and perspectives. Front Oncol 2023; 13:1122699. [PMID: 36968995 PMCID: PMC10031020 DOI: 10.3389/fonc.2023.1122699] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Accepted: 02/22/2023] [Indexed: 03/11/2023] Open
Abstract
Hairy cell leukemia (HCL) is an incurable, rare lymphoproliferative hematological malignancy of mature B cAlthough first line therapy with purine analogues leads to positive results, almost half of HCL patients relapse after 5-10 years, and standard treatment may not be an option due to intolerance or refractoriness. Proliferation and survival of HCL cells is regulated by surrounding accessory cells and soluble signals present in the tumor microenvironment, which actively contributes to disease progression. In vitro studies show that different therapeutic approaches tested in HCL impact the tumor microenvironment, and that this milieu offers a protection affecting treatment efficacy. Herein we explore the effects of the tumor microenvironment to different approved and experimental therapeutic options for HCL. Dissecting the complex interactions between leukemia cells and their milieu will be essential to develop new targeted therapies for HCL patients.
Collapse
Affiliation(s)
- Ernesto Gargiulo
- Tumor Stroma Interactions – Department of Cancer Research, Luxembourg Institute of HealthLuxembourg, Luxembourg
- Chronic Lymphocytic Leukemia Laboratory, Department of Hematology, Rigshospitalet, Copenhagen, Denmark
- PERSIMUNE, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark
| | - Mirta Giordano
- Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, Buenos Aires, Argentina
| | - Carsten U. Niemann
- Chronic Lymphocytic Leukemia Laboratory, Department of Hematology, Rigshospitalet, Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Etienne Moussay
- Tumor Stroma Interactions – Department of Cancer Research, Luxembourg Institute of HealthLuxembourg, Luxembourg
- *Correspondence: Pablo Elías Morande, ; ; Etienne Moussay, ; Jérôme Paggetti,
| | - Jérôme Paggetti
- Tumor Stroma Interactions – Department of Cancer Research, Luxembourg Institute of HealthLuxembourg, Luxembourg
- *Correspondence: Pablo Elías Morande, ; ; Etienne Moussay, ; Jérôme Paggetti,
| | - Pablo Elías Morande
- Tumor Stroma Interactions – Department of Cancer Research, Luxembourg Institute of HealthLuxembourg, Luxembourg
- Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, Buenos Aires, Argentina
- *Correspondence: Pablo Elías Morande, ; ; Etienne Moussay, ; Jérôme Paggetti,
| |
Collapse
|
4
|
Gargiulo E, Viry E, Morande PE, Largeot A, Gonder S, Xian F, Ioannou N, Benzarti M, Kleine Borgmann FB, Mittelbronn M, Dittmar G, Nazarov PV, Meiser J, Stamatopoulos B, Ramsay AG, Moussay E, Paggetti J. Extracellular Vesicle Secretion by Leukemia Cells In Vivo Promotes CLL Progression by Hampering Antitumor T-cell Responses. Blood Cancer Discov 2023; 4:54-77. [PMID: 36108149 PMCID: PMC9816815 DOI: 10.1158/2643-3230.bcd-22-0029] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Revised: 07/04/2022] [Accepted: 09/07/2022] [Indexed: 01/11/2023] Open
Abstract
Small extracellular vesicle (sEV, or exosome) communication among cells in the tumor microenvironment has been modeled mainly in cell culture, whereas their relevance in cancer pathogenesis and progression in vivo is less characterized. Here we investigated cancer-microenvironment interactions in vivo using mouse models of chronic lymphocytic leukemia (CLL). sEVs isolated directly from CLL tissue were enriched in specific miRNA and immune-checkpoint ligands. Distinct molecular components of tumor-derived sEVs altered CD8+ T-cell transcriptome, proteome, and metabolome, leading to decreased functions and cell exhaustion ex vivo and in vivo. Using antagomiRs and blocking antibodies, we defined specific cargo-mediated alterations on CD8+ T cells. Abrogating sEV biogenesis by Rab27a/b knockout dramatically delayed CLL pathogenesis. This phenotype was rescued by exogenous leukemic sEV or CD8+ T-cell depletion. Finally, high expression of sEV-related genes correlated with poor outcomes in CLL patients, suggesting sEV profiling as a prognostic tool. In conclusion, sEVs shape the immune microenvironment during CLL progression. SIGNIFICANCE sEVs produced in the leukemia microenvironment impair CD8+ T-cell mediated antitumor immune response and are indispensable for leukemia progression in vivo in murine preclinical models. In addition, high expression of sEV-related genes correlated with poor survival and unfavorable clinical parameters in CLL patients. See related commentary by Zhong and Guo, p. 5. This article is highlighted in the In This Issue feature, p. 1.
Collapse
Affiliation(s)
- Ernesto Gargiulo
- Tumor–Stroma Interactions Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| | - Elodie Viry
- Tumor–Stroma Interactions Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| | - Pablo Elías Morande
- Tumor–Stroma Interactions Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.,Instituto de Medicina Experimental (IMEX)-CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina
| | - Anne Largeot
- Tumor–Stroma Interactions Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| | - Susanne Gonder
- Tumor–Stroma Interactions Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.,Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Feng Xian
- Proteomics of Cellular Signaling, Department of Infection and Immunity, Luxembourg Institute of Health, Strassen, Luxembourg
| | - Nikolaos Ioannou
- School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
| | - Mohaned Benzarti
- Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.,Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| | - Felix Bruno Kleine Borgmann
- Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.,Department of Neurosurgery, Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg.,Luxembourg Centre of Neuropathology, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| | - Michel Mittelbronn
- Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.,Luxembourg Centre of Neuropathology, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.,Luxembourg Centre of Neuropathology, University of Luxembourg, Esch-sur-Alzette, Luxembourg.,Department of Life Sciences and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.,National Center of Pathology, Laboratoire national de santé (LNS), Dudelange, Luxembourg.,Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Gunnar Dittmar
- Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.,Proteomics of Cellular Signaling, Department of Infection and Immunity, Luxembourg Institute of Health, Strassen, Luxembourg
| | - Petr V. Nazarov
- Multiomics Data Science Group, Department of Cancer Research, Luxembourg Institute of Health, Strassen, Luxembourg
| | - Johannes Meiser
- Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| | - Basile Stamatopoulos
- Laboratory of Clinical Cell Therapy, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium
| | - Alan G. Ramsay
- School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
| | - Etienne Moussay
- Tumor–Stroma Interactions Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.,Corresponding Authors: Jérôme Paggetti, Department of Cancer Research, Luxembourg Institute of Health, 6, Rue Nicolas-Ernest Barblé, Luxembourg, L-1210, Luxembourg. Phone: 352-26970-344; E-mail: ; and Etienne Moussay. Phone: 352-26970-232; E-mail:
| | - Jérôme Paggetti
- Tumor–Stroma Interactions Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.,Corresponding Authors: Jérôme Paggetti, Department of Cancer Research, Luxembourg Institute of Health, 6, Rue Nicolas-Ernest Barblé, Luxembourg, L-1210, Luxembourg. Phone: 352-26970-344; E-mail: ; and Etienne Moussay. Phone: 352-26970-232; E-mail:
| |
Collapse
|
5
|
Goral A, Firczuk M, Fidyt K, Sledz M, Simoncello F, Siudakowska K, Pagano G, Moussay E, Paggetti J, Nowakowska P, Gobessi S, Barankiewicz J, Salomon-Perzynski A, Benvenuti F, Efremov DG, Juszczynski P, Lech-Maranda E, Muchowicz A. A Specific CD44lo CD25lo Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia. Front Immunol 2022; 13:781364. [PMID: 35296093 PMCID: PMC8918500 DOI: 10.3389/fimmu.2022.781364] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Accepted: 02/07/2022] [Indexed: 12/17/2022] Open
Abstract
Regulatory T cells (Tregs) are capable of inhibiting the proliferation, activation and function of T cells and play an important role in impeding the immune response to cancer. In chronic lymphocytic leukemia (CLL) a dysfunctional immune response and elevated percentage of effector-like phenotype Tregs have been described. In this study, using the Eµ-TCL1 mouse model of CLL, we evaluated the changes in the Tregs phenotype and their expansion at different stages of leukemia progression. Importantly, we show that Tregs depletion in DEREG mice triggered the expansion of new anti-leukemic cytotoxic T cell clones leading to leukemia eradication. In TCL1 leukemia-bearing mice we identified and characterized a specific Tregs subpopulation, the phenotype of which suggests its role in the formation of an immunosuppressive microenvironment, supportive for leukemia survival and proliferation. This observation was also confirmed by the gene expression profile analysis of these TCL1-specific Tregs. The obtained data on Tregs are consistent with those described so far, however, above all show that the changes in the Tregs phenotype described in CLL result from the formation of a specific, described in this study Tregs subpopulation. In addition, functional tests revealed the ability of Tregs to inhibit T cells that recognize model antigens expressed by leukemic cells. Moreover, inhibition of Tregs with a MALT1 inhibitor provided a therapeutic benefit, both as monotherapy and also when combined with an immune checkpoint inhibitor. Altogether, activation of Tregs appears to be crucial for CLL progression.
Collapse
Affiliation(s)
- Agnieszka Goral
- Department of Immunology, Medical University of Warsaw, Warsaw, Poland
| | | | - Klaudyna Fidyt
- Department of Immunology, Medical University of Warsaw, Warsaw, Poland
| | - Marta Sledz
- Department of Immunology, Medical University of Warsaw, Warsaw, Poland
| | - Francesca Simoncello
- Cellular Immunology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | | | - Giulia Pagano
- Tumor-Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Etienne Moussay
- Tumor-Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Jérôme Paggetti
- Tumor-Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | | | - Stefania Gobessi
- Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | - Joanna Barankiewicz
- Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
| | | | - Federica Benvenuti
- Cellular Immunology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | - Dimitar G. Efremov
- Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | - Przemyslaw Juszczynski
- Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
| | - Ewa Lech-Maranda
- Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
| | - Angelika Muchowicz
- Department of Immunology, Medical University of Warsaw, Warsaw, Poland
- *Correspondence: Angelika Muchowicz,
| |
Collapse
|
6
|
Moussay E, Seiffert M, Paggetti J. Editorial: New Insights Into the Complexity of Tumor Immunology in B-Cell Malignancies: Prognostic and Predictive Biomarkers and Therapy. Front Oncol 2022; 11:841763. [PMID: 35111688 PMCID: PMC8801534 DOI: 10.3389/fonc.2021.841763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 12/31/2021] [Indexed: 11/21/2022] Open
Affiliation(s)
- Etienne Moussay
- Tumor-Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Martina Seiffert
- Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Jérôme Paggetti
- Tumor-Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
| |
Collapse
|
7
|
Seiffert M, Moussay E, Paggetti J. Editorial: New Insights into the Complexity of Tumor Immunology in B-cell Malignancies: Tumor Immunology and Immunotherapy. Front Oncol 2022; 12:853620. [PMID: 35186775 PMCID: PMC8851321 DOI: 10.3389/fonc.2022.853620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Accepted: 01/14/2022] [Indexed: 11/13/2022] Open
Affiliation(s)
- Martina Seiffert
- Division of Molecular Genetics, Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
- *Correspondence: Martina Seiffert,
| | - Etienne Moussay
- Tumor-Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Jérôme Paggetti
- Tumor-Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
| |
Collapse
|
8
|
Paggetti J, Seiffert M, Moussay E. Editorial: New Insights Into the Complexity of Tumor Immunology in B-Cell Malignancies: Disease Biology and Signaling. Front Oncol 2021; 11:820984. [PMID: 34976849 PMCID: PMC8714831 DOI: 10.3389/fonc.2021.820984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Accepted: 11/29/2021] [Indexed: 11/13/2022] Open
Affiliation(s)
- Jérôme Paggetti
- Tumor-Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
- *Correspondence: Jérôme Paggetti,
| | - Martina Seiffert
- Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Etienne Moussay
- Tumor-Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
| |
Collapse
|
9
|
Wurzer H, Filali L, Hoffmann C, Krecke M, Biolato AM, Mastio J, De Wilde S, François JH, Largeot A, Berchem G, Paggetti J, Moussay E, Thomas C. Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling. Front Immunol 2021; 12:619069. [PMID: 34108958 PMCID: PMC8181408 DOI: 10.3389/fimmu.2021.619069] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Accepted: 04/23/2021] [Indexed: 01/24/2023] Open
Abstract
Natural killer (NK) cells are innate effector lymphocytes with strong antitumor effects against hematologic malignancies such as chronic lymphocytic leukemia (CLL). However, NK cells fail to control CLL progression on the long term. For effective lysis of their targets, NK cells use a specific cell-cell interface, known as the immunological synapse (IS), whose assembly and effector function critically rely on dynamic cytoskeletal changes in NK cells. Here we explored the role of CLL cell actin cytoskeleton during NK cell attack. We found that CLL cells can undergo fast actin cytoskeleton remodeling which is characterized by a NK cell contact-induced accumulation of actin filaments at the IS. Such polarization of the actin cytoskeleton was strongly associated with resistance against NK cell-mediated cytotoxicity and reduced amounts of the cell-death inducing molecule granzyme B in target CLL cells. Selective pharmacological targeting of the key actin regulator Cdc42 abrogated the capacity of CLL cells to reorganize their actin cytoskeleton during NK cell attack, increased levels of transferred granzyme B and restored CLL cell susceptibility to NK cell cytotoxicity. This resistance mechanism was confirmed in primary CLL cells from patients. In addition, pharmacological inhibition of actin dynamics in combination with blocking antibodies increased conjugation frequency and improved CLL cell elimination by NK cells. Together our results highlight the critical role of CLL cell actin cytoskeleton in driving resistance against NK cell cytotoxicity and provide new potential therapeutic point of intervention to target CLL immune escape.
Collapse
Affiliation(s)
- Hannah Wurzer
- Cytoskeleton and Cancer Progression, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg.,Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Liza Filali
- Cytoskeleton and Cancer Progression, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| | - Céline Hoffmann
- Cytoskeleton and Cancer Progression, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| | - Max Krecke
- Cytoskeleton and Cancer Progression, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg.,Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Andrea Michela Biolato
- Cytoskeleton and Cancer Progression, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg.,Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Jérôme Mastio
- Cytoskeleton and Cancer Progression, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| | - Sigrid De Wilde
- Department of Hemato-Oncology, Central Hospitalier du Luxembourg, Luxembourg City, Luxembourg
| | - Jean Hugues François
- Laboratory of Hematology, Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg
| | - Anne Largeot
- Tumor-Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| | - Guy Berchem
- Department of Hemato-Oncology, Central Hospitalier du Luxembourg, Luxembourg City, Luxembourg.,Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| | - Jérôme Paggetti
- Tumor-Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| | - Etienne Moussay
- Tumor-Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| | - Clément Thomas
- Cytoskeleton and Cancer Progression, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| |
Collapse
|
10
|
Gargiulo E, Morande PE, Largeot A, Moussay E, Paggetti J. Diagnostic and Therapeutic Potential of Extracellular Vesicles in B-Cell Malignancies. Front Oncol 2020; 10:580874. [PMID: 33117718 PMCID: PMC7550802 DOI: 10.3389/fonc.2020.580874] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Accepted: 09/04/2020] [Indexed: 12/15/2022] Open
Abstract
Extracellular vesicles (EV), comprising microvesicles and exosomes, are particles released by every cell of an organism, found in all biological fluids, and commonly involved in cell-to-cell communication through the transfer of cargo materials such as miRNA, proteins, and immune-related ligands (e.g., FasL and PD-L1). An important characteristic of EV is that their composition, abundance, and roles are tightly related to the parental cells. This translates into a higher release of characteristic pro-tumor EV by cancer cells that leads to harming signals toward healthy microenvironment cells. In line with this, the key role of tumor-derived EV in cancer progression was demonstrated in multiple studies and is considered a hot topic in the field of oncology. Given their characteristics, tumor-derived EV carry important information concerning the state of tumor cells. This can be used to follow the outset, development, and progression of the neoplasia and to evaluate the design of appropriate therapeutic strategies. In keeping with this, the present brief review will focus on B-cell malignancies and how EV can be used as potential biomarkers to follow disease progression and stage. Furthermore, we will explore several proposed strategies aimed at using biologically engineered EV for treatment (e.g., drug delivery mechanisms) as well as for impairing the biogenesis, release, and internalization of cancer-derived EV, with the final objective to disrupt tumor–microenvironment communication.
Collapse
Affiliation(s)
- Ernesto Gargiulo
- Tumor-Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Pablo Elías Morande
- Tumor-Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg.,Instituto de Medicina Experimental (IMEX)-CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina
| | - Anne Largeot
- Tumor-Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Etienne Moussay
- Tumor-Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Jérôme Paggetti
- Tumor-Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg
| |
Collapse
|
11
|
Causse SZ, Marcion G, Chanteloup G, Uyanik B, Boudesco C, Grigorash BB, Douhard R, Dias AMM, Dumetier B, Dondaine L, Gozzi GJ, Moussay E, Paggetti J, Mirjolet C, de Thonel A, Dubrez L, Demidov ON, Gobbo J, Garrido C. HSP110 translocates to the nucleus upon genotoxic chemotherapy and promotes DNA repair in colorectal cancer cells. Oncogene 2018; 38:2767-2777. [PMID: 30542121 DOI: 10.1038/s41388-018-0616-2] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Revised: 10/30/2018] [Accepted: 11/17/2018] [Indexed: 12/29/2022]
Abstract
A multicenter clinical study demonstrated the presence of a loss-of-function HSP110 mutation in about 15% of colorectal cancers, which resulted from an alternative splicing and was produced at the detriment of wild-type HSP110. Patients expressing low levels of wild-type HSP110 had excellent outcomes (i.e. response to an oxaliplatin-based chemotherapy). Here, we show in vitro, in vivo, and in patients' biopsies that HSP110 co-localizes with DNA damage (γ-H2AX). In colorectal cancer cells, HSP110 translocates into the nucleus upon treatment with genotoxic chemotherapy such as oxaliplatin. Furthermore, we show that HSP110 interacts with the Ku70/Ku80 heterodimer, an essential element of the non-homologous end joining (NHEJ) repair machinery. We also demonstrate by evaluating the resolved 53BP1 foci that depletion in HSP110 impairs repair steps of the NHEJ pathway, which is associated with an increase in DNA double-strand breaks and in the cells' sensitivity to oxaliplatin. HSP110-depleted cells sensitization to oxaliplatin-induced DNA damage is abolished upon re-expression of HSP110. Confirming a role for HSP110 in DNA non-homologous repair, SCR7 and NU7026, two inhibitors of the NHEJ pathway, circumvents HSP110-induced resistance to chemotherapy. In conclusion, HSP110 through its interaction with the Ku70/80 heterodimer may participate in DNA repair, thereby inducing a protection against genotoxic therapy.
Collapse
Affiliation(s)
- Sebastien Z Causse
- INSERM UMR 1231, «Equipe labellisée» Ligue National contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France.,Université de Bourgogne-Franche Comté, Dijon, France
| | - Guillaume Marcion
- INSERM UMR 1231, «Equipe labellisée» Ligue National contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France.,Université de Bourgogne-Franche Comté, Dijon, France
| | - Gaëtan Chanteloup
- INSERM UMR 1231, «Equipe labellisée» Ligue National contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France.,Université de Bourgogne-Franche Comté, Dijon, France
| | - Burhan Uyanik
- INSERM UMR 1231, «Equipe labellisée» Ligue National contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France.,Université de Bourgogne-Franche Comté, Dijon, France
| | - Christophe Boudesco
- INSERM UMR 1231, «Equipe labellisée» Ligue National contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France.,Université de Bourgogne-Franche Comté, Dijon, France
| | - Bogdan B Grigorash
- INSERM UMR 1231, «Equipe labellisée» Ligue National contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France.,Université de Bourgogne-Franche Comté, Dijon, France
| | - Romain Douhard
- INSERM UMR 1231, «Equipe labellisée» Ligue National contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France.,Université de Bourgogne-Franche Comté, Dijon, France
| | - Alexandre M M Dias
- INSERM UMR 1231, «Equipe labellisée» Ligue National contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France.,Université de Bourgogne-Franche Comté, Dijon, France
| | - Baptiste Dumetier
- INSERM UMR 1231, «Equipe labellisée» Ligue National contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France.,Université de Bourgogne-Franche Comté, Dijon, France
| | - Lucile Dondaine
- INSERM UMR 1231, «Equipe labellisée» Ligue National contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France.,Université de Bourgogne-Franche Comté, Dijon, France
| | - Gustavo J Gozzi
- INSERM UMR 1231, «Equipe labellisée» Ligue National contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France.,Université de Bourgogne-Franche Comté, Dijon, France
| | - Etienne Moussay
- Luxembourg Institute of Health, 84, Val Fleuri, L-1526, Luxembourg, Luxembourg
| | - Jérôme Paggetti
- Luxembourg Institute of Health, 84, Val Fleuri, L-1526, Luxembourg, Luxembourg
| | - Céline Mirjolet
- Anticancer Center Georges François Leclerc-Unicancer, Dijon Cedex, France
| | - Aurélie de Thonel
- Unité « Epigénétique et Destin cellulaire», Université Paris Diderot, Paris, France
| | - Laurence Dubrez
- INSERM UMR 1231, «Equipe labellisée» Ligue National contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France.,Université de Bourgogne-Franche Comté, Dijon, France
| | - Oleg N Demidov
- INSERM UMR 1231, «Equipe labellisée» Ligue National contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France.,Université de Bourgogne-Franche Comté, Dijon, France
| | - Jessica Gobbo
- INSERM UMR 1231, «Equipe labellisée» Ligue National contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France.,Université de Bourgogne-Franche Comté, Dijon, France.,Anticancer Center Georges François Leclerc-Unicancer, Dijon Cedex, France
| | - Carmen Garrido
- INSERM UMR 1231, «Equipe labellisée» Ligue National contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France. .,Université de Bourgogne-Franche Comté, Dijon, France. .,Anticancer Center Georges François Leclerc-Unicancer, Dijon Cedex, France.
| |
Collapse
|
12
|
Haderk F, Schulz R, Iskar M, Cid LL, Worst T, Willmund KV, Schulz A, Warnken U, Seiler J, Benner A, Nessling M, Zenz T, Göbel M, Dürig J, Diederichs S, Paggetti J, Moussay E, Stilgenbauer S, Zapatka M, Lichter P, Seiffert M. Tumor-derived exosomes modulate PD-L1 expression in monocytes. Sci Immunol 2017; 2:2/13/eaah5509. [PMID: 28754746 DOI: 10.1126/sciimmunol.aah5509] [Citation(s) in RCA: 213] [Impact Index Per Article: 30.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2016] [Revised: 03/23/2017] [Accepted: 06/12/2017] [Indexed: 12/14/2022]
Abstract
In chronic lymphocytic leukemia (CLL), monocytes and macrophages are skewed toward protumorigenic phenotypes, including the release of tumor-supportive cytokines and the expression of immunosuppressive molecules such as programmed cell death 1 ligand 1 (PD-L1). To understand the mechanism driving protumorigenic skewing in CLL, we evaluated the role of tumor cell-derived exosomes in the cross-talk with monocytes. We carried out RNA sequencing and proteome analyses of CLL-derived exosomes and identified noncoding Y RNA hY4 as a highly abundant RNA species that is enriched in exosomes from plasma of CLL patients compared with healthy donor samples. Transfer of CLL-derived exosomes or hY4 alone to monocytes resulted in key CLL-associated phenotypes, including the release of cytokines, such as C-C motif chemokine ligand 2 (CCL2), CCL4, and interleukin-6, and the expression of PD-L1. These responses were abolished in Toll-like receptor 7 (TLR7)-deficient monocytes, suggesting exosomal hY4 as a driver of TLR7 signaling. Pharmacologic inhibition of endosomal TLR signaling resulted in a substantially reduced activation of monocytes in vitro and attenuated CLL development in vivo. Our results indicate that exosome-mediated transfer of noncoding RNAs to monocytes contributes to cancer-related inflammation and concurrent immune escape via PD-L1 expression.
Collapse
Affiliation(s)
- Franziska Haderk
- Department of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Ralph Schulz
- Department of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Murat Iskar
- Department of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Laura Llaó Cid
- Department of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Thomas Worst
- Division of Signaling and Functional Genomics, DKFZ, Heidelberg, Germany
| | - Karolin V Willmund
- Department of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Angela Schulz
- Department of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Genomics and Proteomics Core Facility, DKFZ, Heidelberg, Germany
| | - Uwe Warnken
- Genomics and Proteomics Core Facility, DKFZ, Heidelberg, Germany
| | - Jana Seiler
- Division of RNA Biology and Cancer (B150), DKFZ, Heidelberg, Germany
| | - Axel Benner
- Division of Biostatistics, DKFZ, Heidelberg, Germany
| | | | - Thorsten Zenz
- Department of Molecular Therapy in Hematology and Oncology and Department of Translational Oncology, National Center for Tumor Diseases (NCT); DKFZ; and Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany
| | - Maria Göbel
- Department of Hematology, Essen University Hospital, Essen, Germany
| | - Jan Dürig
- Department of Hematology, Essen University Hospital, Essen, Germany
| | - Sven Diederichs
- Division of RNA Biology and Cancer (B150), DKFZ, Heidelberg, Germany.,Division of Cancer Research, Department of Thoracic Surgery, Medical Center-Faculty of Medicine, University of Freiburg, Freiburg, Germany.,German Cancer Consortium (DKTK), Freiburg, Germany
| | - Jérôme Paggetti
- Laboratory of Experimental Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| | - Etienne Moussay
- Laboratory of Experimental Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg
| | | | - Marc Zapatka
- Department of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Peter Lichter
- Department of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Martina Seiffert
- Department of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
| |
Collapse
|
13
|
Viry E, Noman MZ, Arakelian T, Lequeux A, Chouaib S, Berchem G, Moussay E, Paggetti J, Janji B. Hijacker of the Antitumor Immune Response: Autophagy Is Showing Its Worst Facet. Front Oncol 2016; 6:246. [PMID: 27917371 PMCID: PMC5114287 DOI: 10.3389/fonc.2016.00246] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2016] [Accepted: 11/04/2016] [Indexed: 12/19/2022] Open
Abstract
Macroautophagy (hereafter referred to as autophagy) is a housekeeping process constitutively executed at basal level in all cells to promote cellular homeostasis by regulating organelle and protein turnover. However, autophagy deregulation caused by several stress factors, such as hypoxia, is prevalent in many cancers. It is now well established that autophagy can act as tumor suppressor or tumor promoter depending on tumor type, stage, and genetic context. In developed tumors, autophagy promotes the survival of cancer cells and therefore operates as a cell resistance mechanism. Emerging evidence point to the prominent role of autophagy in disabling the antitumor immune response by multiple overlapping mechanisms leading to tumor escape from immune cell attack mediated by both natural killer cells and cytotoxic T-lymphocytes. Such a role has inspired significant interest in applying anti-autophagy therapies as an entirely new approach to overcome tumor escape from immune surveillance, which constitutes so far a major challenge in developing more effective cancer immunotherapies. In this review, we will summarize recent reports describing how tumor cells, by activating autophagy, manage to hijack the immune system. In particular, we will focus on the emerging role of hypoxia-induced autophagy in shaping the antitumor immune response and in allowing tumor cells to outmaneuver an effective immune response and escape immunosurveillance. In keeping with this, we strongly believe that autophagy represents an attractive future therapeutic target to develop innovative and effective cancer immunotherapeutic approaches.
Collapse
Affiliation(s)
- Elodie Viry
- Laboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health , Luxembourg City , Luxembourg
| | - Muhammad Zaeem Noman
- Laboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg; INSERM U1186, Gustave Roussy Cancer Center, Villejuif, France
| | - Tsolère Arakelian
- Laboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health , Luxembourg City , Luxembourg
| | - Audrey Lequeux
- Laboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health , Luxembourg City , Luxembourg
| | - Salem Chouaib
- INSERM U1186, Gustave Roussy Cancer Center , Villejuif , France
| | - Guy Berchem
- Laboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg; Department of Hemato-Oncology, Centre Hospitalier du Luxembourg, Luxembourg City, Luxembourg
| | - Etienne Moussay
- Laboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health , Luxembourg City , Luxembourg
| | - Jérôme Paggetti
- Laboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health , Luxembourg City , Luxembourg
| | - Bassam Janji
- Laboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health , Luxembourg City , Luxembourg
| |
Collapse
|
14
|
Baginska J, Viry E, Paggetti J, Medves S, Berchem G, Moussay E, Janji B. The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol 2013; 4:490. [PMID: 24400010 PMCID: PMC3872331 DOI: 10.3389/fimmu.2013.00490] [Citation(s) in RCA: 138] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2013] [Accepted: 12/13/2013] [Indexed: 12/27/2022] Open
Abstract
Considerable evidence has been gathered over the last 10 years showing that the tumor microenvironment (TME) is not simply a passive recipient of immune cells, but an active participant in the establishment of immunosuppressive conditions. It is now well documented that hypoxia, within the TME, affects the functions of immune effectors including natural killer (NK) cells by multiple overlapping mechanisms. Indeed, each cell in the TME, irrespective of its transformation status, has the capacity to adapt to the hostile TME and produce immune modulatory signals or mediators affecting the function of immune cells either directly or through the stimulation of other cells present in the tumor site. This observation has led to intense research efforts focused mainly on tumor-derived factors. Notably, it has become increasingly clear that tumor cells secrete a number of environmental factors such as cytokines, growth factors, exosomes, and microRNAs impacting the immune cell response. Moreover, tumor cells in hostile microenvironments may activate their own intrinsic resistance mechanisms, such as autophagy, to escape the effective immune response. Such adaptive mechanisms may also include the ability of tumor cells to modify their metabolism and release several metabolites to impair the function of immune cells. In this review, we summarize the different mechanisms involved in the TME that affect the anti-tumor immune function of NK cells.
Collapse
Affiliation(s)
- Joanna Baginska
- Laboratory of Experimental Hemato-Oncology, Department of Oncology, Public Research Center for Health (CRP-Santé) , Luxembourg City , Luxembourg
| | - Elodie Viry
- Laboratory of Experimental Hemato-Oncology, Department of Oncology, Public Research Center for Health (CRP-Santé) , Luxembourg City , Luxembourg
| | - Jérôme Paggetti
- Laboratory of Experimental Hemato-Oncology, Department of Oncology, Public Research Center for Health (CRP-Santé) , Luxembourg City , Luxembourg
| | - Sandrine Medves
- Laboratory of Experimental Hemato-Oncology, Department of Oncology, Public Research Center for Health (CRP-Santé) , Luxembourg City , Luxembourg
| | - Guy Berchem
- Laboratory of Experimental Hemato-Oncology, Department of Oncology, Public Research Center for Health (CRP-Santé) , Luxembourg City , Luxembourg
| | - Etienne Moussay
- Laboratory of Experimental Hemato-Oncology, Department of Oncology, Public Research Center for Health (CRP-Santé) , Luxembourg City , Luxembourg
| | - Bassam Janji
- Laboratory of Experimental Hemato-Oncology, Department of Oncology, Public Research Center for Health (CRP-Santé) , Luxembourg City , Luxembourg
| |
Collapse
|
15
|
Largeot A, Paggetti J, Broséus J, Aucagne R, Lagrange B, Martin RZ, Berthelet J, Quéré R, Lucchi G, Ducoroy P, Bastie JN, Delva L. Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2013; 1833:3054-3063. [DOI: 10.1016/j.bbamcr.2013.08.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2013] [Revised: 07/26/2013] [Accepted: 08/13/2013] [Indexed: 01/07/2023]
|
16
|
Lagrange B, Martin RZ, Droin N, Aucagne R, Paggetti J, Largeot A, Itzykson R, Solary E, Delva L, Bastie JN. A role for miR-142-3p in colony-stimulating factor 1-induced monocyte differentiation into macrophages. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2013; 1833:1936-46. [DOI: 10.1016/j.bbamcr.2013.04.007] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/06/2012] [Revised: 04/01/2013] [Accepted: 04/09/2013] [Indexed: 01/24/2023]
|
17
|
Aucagne R, Droin N, Paggetti J, Lagrange B, Largeot A, Hammann A, Bataille A, Martin L, Yan KP, Fenaux P, Losson R, Solary E, Bastie JN, Delva L. Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest 2011; 121:2361-70. [PMID: 21537084 PMCID: PMC3104753 DOI: 10.1172/jci45213] [Citation(s) in RCA: 88] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2010] [Accepted: 03/08/2011] [Indexed: 12/27/2022] Open
Abstract
Transcription intermediary factor 1γ (TIF1γ) was suggested to play a role in erythropoiesis. However, how TIF1γ regulates the development of different blood cell lineages and whether TIF1γ is involved in human hematological malignancies remain to be determined. Here we have shown that TIF1γ was a tumor suppressor in mouse and human chronic myelomonocytic leukemia (CMML). Loss of Tif1g in mouse HSCs favored the expansion of the granulo-monocytic progenitor compartment. Furthermore, Tif1g deletion induced the age-dependent appearance of a cell-autonomous myeloproliferative disorder in mice that recapitulated essential characteristics of human CMML. TIF1γ was almost undetectable in leukemic cells of 35% of CMML patients. This downregulation was related to the hypermethylation of CpG sequences and specific histone modifications in the gene promoter. A demethylating agent restored the normal epigenetic status of the TIF1G promoter in human cells, which correlated with a reestablishment of TIF1γ expression. Together, these results demonstrate that TIF1G is an epigenetically regulated tumor suppressor gene in hematopoietic cells and suggest that changes in TIF1γ expression may be a biomarker of response to demethylating agents in CMML.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Aging/genetics
- Animals
- Antimetabolites, Antineoplastic/pharmacology
- Antimetabolites, Antineoplastic/therapeutic use
- Azacitidine/analogs & derivatives
- Azacitidine/pharmacology
- Azacitidine/therapeutic use
- Base Sequence
- Cell Differentiation
- DNA Methylation
- Decitabine
- Female
- Gene Expression Regulation, Leukemic
- Genes, Tumor Suppressor
- Hematopoiesis/genetics
- Hematopoiesis/physiology
- Hematopoietic Stem Cells/pathology
- Humans
- Leukemia, Myelomonocytic, Chronic/drug therapy
- Leukemia, Myelomonocytic, Chronic/genetics
- Leukemia, Myelomonocytic, Chronic/pathology
- Male
- Mice
- Mice, Knockout
- Middle Aged
- Molecular Sequence Data
- Neoplasm Proteins/biosynthesis
- Neoplasm Proteins/genetics
- Neoplasm Proteins/physiology
- Promoter Regions, Genetic
- Receptor, Macrophage Colony-Stimulating Factor/biosynthesis
- Receptor, Macrophage Colony-Stimulating Factor/genetics
- Specific Pathogen-Free Organisms
- Transcription Factors/deficiency
- Transcription Factors/genetics
- Transcription Factors/physiology
Collapse
Affiliation(s)
- Romain Aucagne
- Inserm UMR 866, University of Burgundy, Dijon, France.
IFR “Santé-STIC,” University of Burgundy, Dijon, France.
Inserm UMR 1009, Integrated Research Cancer Institute Villejuif (IRCIV), Institut Gustave Roussy, Villejuif, France.
Flow Cytometry Facility,
Cellular Imagery Facility, and
Department of Pathology, University Hospital, Dijon, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Functional Genomics, CNRS UMR 7104, Inserm U964, Louis Pasteur University, Collège de France, Illkirch, France.
University Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP) and University of Paris 13, Bobigny, France.
University Hospital, Clinical Hematology Department, Dijon, France
| | - Nathalie Droin
- Inserm UMR 866, University of Burgundy, Dijon, France.
IFR “Santé-STIC,” University of Burgundy, Dijon, France.
Inserm UMR 1009, Integrated Research Cancer Institute Villejuif (IRCIV), Institut Gustave Roussy, Villejuif, France.
Flow Cytometry Facility,
Cellular Imagery Facility, and
Department of Pathology, University Hospital, Dijon, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Functional Genomics, CNRS UMR 7104, Inserm U964, Louis Pasteur University, Collège de France, Illkirch, France.
University Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP) and University of Paris 13, Bobigny, France.
University Hospital, Clinical Hematology Department, Dijon, France
| | - Jérôme Paggetti
- Inserm UMR 866, University of Burgundy, Dijon, France.
IFR “Santé-STIC,” University of Burgundy, Dijon, France.
Inserm UMR 1009, Integrated Research Cancer Institute Villejuif (IRCIV), Institut Gustave Roussy, Villejuif, France.
Flow Cytometry Facility,
Cellular Imagery Facility, and
Department of Pathology, University Hospital, Dijon, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Functional Genomics, CNRS UMR 7104, Inserm U964, Louis Pasteur University, Collège de France, Illkirch, France.
University Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP) and University of Paris 13, Bobigny, France.
University Hospital, Clinical Hematology Department, Dijon, France
| | - Brice Lagrange
- Inserm UMR 866, University of Burgundy, Dijon, France.
IFR “Santé-STIC,” University of Burgundy, Dijon, France.
Inserm UMR 1009, Integrated Research Cancer Institute Villejuif (IRCIV), Institut Gustave Roussy, Villejuif, France.
Flow Cytometry Facility,
Cellular Imagery Facility, and
Department of Pathology, University Hospital, Dijon, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Functional Genomics, CNRS UMR 7104, Inserm U964, Louis Pasteur University, Collège de France, Illkirch, France.
University Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP) and University of Paris 13, Bobigny, France.
University Hospital, Clinical Hematology Department, Dijon, France
| | - Anne Largeot
- Inserm UMR 866, University of Burgundy, Dijon, France.
IFR “Santé-STIC,” University of Burgundy, Dijon, France.
Inserm UMR 1009, Integrated Research Cancer Institute Villejuif (IRCIV), Institut Gustave Roussy, Villejuif, France.
Flow Cytometry Facility,
Cellular Imagery Facility, and
Department of Pathology, University Hospital, Dijon, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Functional Genomics, CNRS UMR 7104, Inserm U964, Louis Pasteur University, Collège de France, Illkirch, France.
University Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP) and University of Paris 13, Bobigny, France.
University Hospital, Clinical Hematology Department, Dijon, France
| | - Arlette Hammann
- Inserm UMR 866, University of Burgundy, Dijon, France.
IFR “Santé-STIC,” University of Burgundy, Dijon, France.
Inserm UMR 1009, Integrated Research Cancer Institute Villejuif (IRCIV), Institut Gustave Roussy, Villejuif, France.
Flow Cytometry Facility,
Cellular Imagery Facility, and
Department of Pathology, University Hospital, Dijon, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Functional Genomics, CNRS UMR 7104, Inserm U964, Louis Pasteur University, Collège de France, Illkirch, France.
University Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP) and University of Paris 13, Bobigny, France.
University Hospital, Clinical Hematology Department, Dijon, France
| | - Amandine Bataille
- Inserm UMR 866, University of Burgundy, Dijon, France.
IFR “Santé-STIC,” University of Burgundy, Dijon, France.
Inserm UMR 1009, Integrated Research Cancer Institute Villejuif (IRCIV), Institut Gustave Roussy, Villejuif, France.
Flow Cytometry Facility,
Cellular Imagery Facility, and
Department of Pathology, University Hospital, Dijon, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Functional Genomics, CNRS UMR 7104, Inserm U964, Louis Pasteur University, Collège de France, Illkirch, France.
University Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP) and University of Paris 13, Bobigny, France.
University Hospital, Clinical Hematology Department, Dijon, France
| | - Laurent Martin
- Inserm UMR 866, University of Burgundy, Dijon, France.
IFR “Santé-STIC,” University of Burgundy, Dijon, France.
Inserm UMR 1009, Integrated Research Cancer Institute Villejuif (IRCIV), Institut Gustave Roussy, Villejuif, France.
Flow Cytometry Facility,
Cellular Imagery Facility, and
Department of Pathology, University Hospital, Dijon, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Functional Genomics, CNRS UMR 7104, Inserm U964, Louis Pasteur University, Collège de France, Illkirch, France.
University Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP) and University of Paris 13, Bobigny, France.
University Hospital, Clinical Hematology Department, Dijon, France
| | - Kai-Ping Yan
- Inserm UMR 866, University of Burgundy, Dijon, France.
IFR “Santé-STIC,” University of Burgundy, Dijon, France.
Inserm UMR 1009, Integrated Research Cancer Institute Villejuif (IRCIV), Institut Gustave Roussy, Villejuif, France.
Flow Cytometry Facility,
Cellular Imagery Facility, and
Department of Pathology, University Hospital, Dijon, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Functional Genomics, CNRS UMR 7104, Inserm U964, Louis Pasteur University, Collège de France, Illkirch, France.
University Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP) and University of Paris 13, Bobigny, France.
University Hospital, Clinical Hematology Department, Dijon, France
| | - Pierre Fenaux
- Inserm UMR 866, University of Burgundy, Dijon, France.
IFR “Santé-STIC,” University of Burgundy, Dijon, France.
Inserm UMR 1009, Integrated Research Cancer Institute Villejuif (IRCIV), Institut Gustave Roussy, Villejuif, France.
Flow Cytometry Facility,
Cellular Imagery Facility, and
Department of Pathology, University Hospital, Dijon, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Functional Genomics, CNRS UMR 7104, Inserm U964, Louis Pasteur University, Collège de France, Illkirch, France.
University Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP) and University of Paris 13, Bobigny, France.
University Hospital, Clinical Hematology Department, Dijon, France
| | - Régine Losson
- Inserm UMR 866, University of Burgundy, Dijon, France.
IFR “Santé-STIC,” University of Burgundy, Dijon, France.
Inserm UMR 1009, Integrated Research Cancer Institute Villejuif (IRCIV), Institut Gustave Roussy, Villejuif, France.
Flow Cytometry Facility,
Cellular Imagery Facility, and
Department of Pathology, University Hospital, Dijon, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Functional Genomics, CNRS UMR 7104, Inserm U964, Louis Pasteur University, Collège de France, Illkirch, France.
University Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP) and University of Paris 13, Bobigny, France.
University Hospital, Clinical Hematology Department, Dijon, France
| | - Eric Solary
- Inserm UMR 866, University of Burgundy, Dijon, France.
IFR “Santé-STIC,” University of Burgundy, Dijon, France.
Inserm UMR 1009, Integrated Research Cancer Institute Villejuif (IRCIV), Institut Gustave Roussy, Villejuif, France.
Flow Cytometry Facility,
Cellular Imagery Facility, and
Department of Pathology, University Hospital, Dijon, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Functional Genomics, CNRS UMR 7104, Inserm U964, Louis Pasteur University, Collège de France, Illkirch, France.
University Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP) and University of Paris 13, Bobigny, France.
University Hospital, Clinical Hematology Department, Dijon, France
| | - Jean-Noël Bastie
- Inserm UMR 866, University of Burgundy, Dijon, France.
IFR “Santé-STIC,” University of Burgundy, Dijon, France.
Inserm UMR 1009, Integrated Research Cancer Institute Villejuif (IRCIV), Institut Gustave Roussy, Villejuif, France.
Flow Cytometry Facility,
Cellular Imagery Facility, and
Department of Pathology, University Hospital, Dijon, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Functional Genomics, CNRS UMR 7104, Inserm U964, Louis Pasteur University, Collège de France, Illkirch, France.
University Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP) and University of Paris 13, Bobigny, France.
University Hospital, Clinical Hematology Department, Dijon, France
| | - Laurent Delva
- Inserm UMR 866, University of Burgundy, Dijon, France.
IFR “Santé-STIC,” University of Burgundy, Dijon, France.
Inserm UMR 1009, Integrated Research Cancer Institute Villejuif (IRCIV), Institut Gustave Roussy, Villejuif, France.
Flow Cytometry Facility,
Cellular Imagery Facility, and
Department of Pathology, University Hospital, Dijon, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Functional Genomics, CNRS UMR 7104, Inserm U964, Louis Pasteur University, Collège de France, Illkirch, France.
University Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP) and University of Paris 13, Bobigny, France.
University Hospital, Clinical Hematology Department, Dijon, France
| |
Collapse
|
18
|
Droin N, Aucagne R, Paggetti J, Lagrange B, Largeot A, Martin L, Fenaux P, Losson R, Solary E, Bastie JN, Delva L. 51 Transcription Intermediary Factor 1 gamma (TIF1γ) is an epigenetically-regulated tumor suppressor gene in human chronic myelomonocytic leukemia. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70053-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
19
|
Abstract
The inv(8)(p11q13) chromosomal abnormality, described in acute myeloid leukaemias (AML), fuses the histone acetyl-transferase (HAT) MYST3 (MOZ) gene with another HAT gene, NCOA2 (TIF2). We generated a transgenic zebrafish in which the MYST3/NCOA2 fusion gene was expressed under control of the spi1 promoter. An AML developed in 2 of 180 MYST3/NCOA2-EGFP-expressing embryos, 14 and 26 months after injection of the fusion gene in a one-cell embryo, respectively. This leukaemia was characterised by an extensive invasion of kidneys by myeloid blast cells. This model, which is the first zebrafish model of AML, demonstrates the oncogenic potency of MYST3/NCOA2 fusion gene.
Collapse
|